Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.
Journal: Nature medicine
Published: March 15, 2025
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 26, 2024
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 18, 2022
Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy.
Journal: Breast cancer research and treatment
Published: May 19, 2021
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 10, 2020
Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
Journal: Cancer
Published: February 07, 2018
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: July 10, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026